4.5 Article

S100A13, a new marker of angiogenesis in human astrocytic gliomas

Journal

JOURNAL OF NEURO-ONCOLOGY
Volume 80, Issue 3, Pages 251-259

Publisher

SPRINGER
DOI: 10.1007/s11060-006-9189-y

Keywords

angiogenesis; brain tumours; FGF1; S100A13; tumour grading; VEGF-A

Funding

  1. NCRR NIH HHS [RR1555] Funding Source: Medline
  2. NHLBI NIH HHS [HL32348, HL35627] Funding Source: Medline

Ask authors/readers for more resources

S100 proteins are Ca2+-binding polypeptides involved in the tumourigenesis of several human neoplasms. S100A13 is a key regulator of the stress-dependent release of FGF1, the prototype of the FGF protein family involved in angiogenesis. Indeed, S100A13 is a copper binding protein able to enhance the export of FGF1 in response to stress in vitro and to induce the formation of a multiprotein aggregate responsible for FGF1 release. We investigated the expression of S100A13 in human astrocytic gliomas in relation to tumour grading and vascularization. A series of 26 astrocytic gliomas was studied to evaluate microvessel density and to assess FGF1, S100A13 and VEGF-A expression. FGF1 was equally expressed in the vast majority of tumours, whereas S100A13 and VEGF-A were significantly up-regulated in high-grade vascularized gliomas. Moreover, both S100A13 and VEGF-A expression significantly correlated with microvessel density and tumour grading. These data suggest that the up-regulation of S100A13 and VEGF-A expression correlates with the activation of angiogenesis in high-grade human astrocytic gliomas.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available